A retrospective, real world study evaluating the apatinib-induced hypertension (HTN) in the treatment of patients with solid tumor
Latest Information Update: 08 Jun 2021
At a glance
- Drugs Rivoceranib (Primary)
- Indications Biliary cancer; Gastrointestinal cancer; Liver cancer; Lung cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 Jun 2021 New trial record
- 14 Apr 2021 Results of performed in patients with gastrointestinal cancer, hepatobiliary cancer, and lung cancer, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension.